HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TECH
Bio-Techne Corporation
TECH's fundamentals are strong: its operating margin rose 11 points to 20% and it turned 25% of its revenue into free cash flow. At 66x earnings, it's trading in line with its usual 63x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TECH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
TECH's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TECH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 34x | $72.84 | — |
| Cheap | 46x | $50.62 | -30% |
| Fair | 63x | $69.08 | -5.2% |
| Current | 66x | $72.84 | — |
| Expensive | 104x | $114 | +57% |
Historical ranges are pointers, not guarantees.
TECH's PE is in its fair range at 66x. If earnings grow as analysts expect, today's price would be 34x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TECH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
TECH has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TECH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.12 | +93% |
| Q3 2026 | $1.10 | +124% |
| Q2 2026 | $1.16 | +152% |
| Q1 2026 | $0.69 | -17% |
| Q4 2025 | $0.51 | -49% |
| Q3 2025 | $0.49 | -48% |
| Q2 2025 | $0.46 | -56% |
| Q1 2025 | $0.83 | -34% |
| Q4 2024 | $1.00 | -28% |
TECH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TECH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TECH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $299.7M | +4.6% |
| Q2 2026 | $321.2M | +1.3% |
| Q1 2026 | $311.4M | -1.5% |
| Q4 2025 | $295.9M | -0.4% |
| Q3 2025 | $286.6M | -1% |
| Q2 2025 | $317M | +3.5% |
| Q1 2025 | $316.2M | +4.2% |
| Q4 2024 | $297M | +9% |
TECH's revenue grew through 2023 and has held roughly level since: $300M last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -4.4 points |
| Q2 2026 | 23% | +31 points |
| Q1 2026 | 24% | +12 points |
| Q4 2025 | 18% | +2.4 points |
| Q3 2025 | 17% | +2.8 points |
| Q2 2025 | -7.5% | -23 points |
| Q1 2025 | 12% | -9.8 points |
| Q4 2024 | 16% | +2 points |
TECH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TECH on cash flow, with more consistent year-over-year improvement.
TECH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $67.2M | +202% |
| Q2 2026 | $86.9M | -6.8% |
| Q1 2026 | $77.6M | +150% |
| Q4 2025 | $76.5M | -1.3% |
| Q3 2025 | $22.2M | -59% |
| Q2 2025 | $93.3M | +62% |
| Q1 2025 | $31M | -52% |
| Q4 2024 | $77.5M | +14% |
TECH's free cash flow has been positive every quarter for six years: $308M over the past year, up 38% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TECH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TECH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +919K shares |
| 1 year | +1% | +1.6M shares |
| 3 years | -2.5% | -4M shares |
| 5 years | -4.1% | -6.7M shares |
| Available history | -0.2% | -272K shares |
TECH has 158M diluted shares, up 1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $41.7M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $24,000 |
| Q2 2025 | $100.1M |
| Q1 2025 | $100M |
| Q2 2024 | — |
| Q1 2024 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TECH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.4x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.4x | Very low |
TECH has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TECH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.9 | Neutral |
| Stochastic | 94.2 | Overbought |
TECH's weekly RSI is 66 (neutral) and its Stochastic is 94 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TECH PE vs Healthcare Sector
| Metric | TECH | Sector median | Relative |
|---|---|---|---|
| PE | 66x | 26x | 156% above |
| PE % | 55 | 29 | 26 pts above |
TECH is trading at 66x earnings, a 156% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TECH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.6 | 0.3% above |
| 20 week MA | $72.3 | 0.8% above |
| 50 week MA | $63.3 | 15% above |
| 100 week MA | $61.0 | 20% above |
| 200 week MA | $67.7 | 7.5% above |
TECH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TECH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.6 | $80.4 | +47% |
| 2021 | $80.4 | $123.7 | +54% |
| 2022 | $123.7 | $82.7 | -33% |
| 2023 | $82.7 | $77.2 | -6.7% |
| 2024 | $77.2 | $73.0 | -5.4% |
| 2025 | $73.0 | $59.2 | -19% |
| 2026 YTD | $59.2 | $72.8 | +23% |
TECH has the edge over HIMS on returns for 2026, with the stronger performance.